Cool site pour acheter des pilules https://jacup.com/ Ne pas se perdre venir sur.

Cv.handjani.08[1].doc

CURRICULUM VITAE
FARHAD HANDJANI, M.D.
ADDRESS:
P.O.Box 71345-1558 Shiraz, Iran Tel.: +98-711-2254360(Home) +98-711-2319049 (Work) Fax: +98-711-2307594 (Work) +98-711-2319049 (Work) Mobile: +98-917-111-2150 E.mail: PERSONAL DATA:
Date of Birth: August 15,1963 Place of Birth: Shiraz, Iran Marital Status: Married Number of Children: One Health Condition: Good EDUCATION:
High School Diploma, 1981 The Peddie School Hightstown, New Jersey, U.S.A. B.A. (Biology and History), 1985 Northwestern University Evanston, Illinois, U.S.A. First Year of Dentistry, 1985-1986 University of Pennsylvania Philadelphia, Pennsylvania, U.S.A. M.D., 1991 Shiraz University of Medical Sciences Shiraz, Iran POST- DOCTORAL TRAINING:
Dermatology Residency, 1991-1995 Department of Dermatology Shiraz University of Medical Sciences Shiraz, Iran FACULTY APPOINTMENTS:
Assistant Professor, 1995-1997 Department of Dermatology Yasuj Universtiy of Medical Sciences Yasuj, Iran Assistant Professor, 1997- 2003 Department of Dermatology Shiraz University of Medical Sciences Shiraz, Iran Associate Professor, 2003-Present Department of Dermatology Shiraz University of Medical Sciences Shiraz, Iran ACADEMIC APPOINTMENTS:
Founding and Chief Editor, 1996-2004 Journal of Yasuj University of Medical Sciences Yasuj University of Medical Sciences Yasuj, Iran Chief Editor, 2000-Present Journal of Medical Research Shiraz University of Medical Sciences Shiraz, Iran Member, Research Consultation Center 1998- Present Shiraz University of Medical Sciences Shiraz, Iran Clinical Monitor, 2001-Present, World Health Switzerland; Completed trials: Leishmania Vaccine Trials immunochemotherapy trial in Sudan; Ongoing trials:Trivalent meningitis trial in Ethiopia; OFLOTUB (TB drug trial) in Kenya. NON- ACADEMIC
APPOINTMENTS:
Writing Workshops, Shiraz University of Medical Sciences, Shiraz, Iran Member, Board of Directors, 2000-Present Fars Society of Dermatology Shiraz, Fars, Iran Member, Secretary-General/Treasurer, 2003-Present, Eastern Commission on Medical Journals, Iranian Ministry of Health MEMBERSHIPS:
Iranian National Medical Council Iranian Society of Dermatology Fars Society of Dermatology International Society of Dermatology HONORS & AWARDS:
High School Diploma with High Honors. Member of the Cum Laude Honor Society, The Peddie School Chapter, Hightstown, N.J., U.S.A, 1981 Member, Alpha Lambda Delta National Scholastic Honor Society for Freshmen, Northwestern University Chapter, Evanston, IL., U.S.A., 1983 Top Tenth Percentile, Medical School Graduates, Shiraz University of Medical Sciences, Shiraz, Iran, 1991 Chancellor’s Commendation Plaque, Yasuj University of Medical Sciences, Yasuj, Iran, 1996 Excellence Dermatology, Shiraz University of Medical Sciences Shiraz, Iran, 1998 Research Fellowship Grant, Rene Touraine Foundation for Dermatological Research, St. Louis Hospital, Paris, France, 1999 Fellowship from Fondation Merieux, Fourth Advanced Vaccinology Course, Annecy, France, May 26- June 6, 2003 Beijing , China, May 20, 2004 Best Teaching Award, 2004-2006, Medical Student Graduates, Shiraz University of Medical Sciences, Shiraz, Iran PRESENTATIONS:
1- Post-Kala-Azar Dermal Leishmaniasis in Iran. The Fourth Asian Dermatological
Congress, Dubai, U.A.E, January 13-15, 1996.
2- Multiple Scalp Nodules: Initial Manifestations of Acute Lymphoblastic Leukemia in an Infant. 5th Congress of the European Society for Pediatric Dermatology, Rotterdam,
the Netherlands, September 4-8, 1996.
3- Becker’s Nevus and Breast Hypoplasia: Report of Case. Pigmentary Disorders from a
Global Perspective, Bali, Indonesia, June 22-24, 1997.
4- Cutaneous Leishmaniasis in Iranian Children: Clinical Features and Management. 8th
International Congress of Pediatric Dermatology, Paris, France, May 17-20, 1998.
5- Epidermolysis Bullosa: A 10-Year Retrospective Study in Iran. 8th International
Congress of Pediatric Dermatology, Paris, France, May 17-20, 1998.
6- The Clinical Spectrum of Cutaneous Leishmaniasis in Iran, 8th International Congress
of Dermatology, Cairo, Egypt, April 16-21, 1999.
7- A Double- blind Randomized Clinical Trial of a Topical Herbal Extract (Z-HE) versus Systemic Meglumine Antimoniate for the Treatment of Cutaneous Leishmaniasis in Iran. 8th International Congress of Dermatology, Cairo, Egypt, April 16-21, 1999.
8- The Healing Effect of Lipid Extracts of Garlic on Warts and Corns. 12th International
Congress of Geographic Medicine, Shiraz, Iran, November 1-4, 1999.
9- Effect of Calendula Officinalis and Plantago Major Extract on Wart. 13th International
Congress of Geographic Medicine, Shiraz, Iran, October 2-5, 2000.
10- Relationship Between Contact Dermatitis and Type of Occupation Among Fars Province Population in 1999. 5th IEA Eastern Mediterranean Regional Scientific
Meeting , Bahrain, October 23-25, 2000.
11- The Expression of Langerin, a Protein Specific to Langerhans Cells, is Decreased in Cutaneous Leishmaniasis. World Leish II, Crete, Greece, May 20-24, 2001.
12- Intralesional Zinc Sulfate 2% in the Treatment of Cutaneous Leishmaniasis. World
Leish II, Crete, Greece, May 20-24, 2001.
13- Herbal Remedies in the Treatment of Dermatological Conditions: The Iranian Experience. 20th World Congress of Dermatology, Paris, France, July 1-5, 2002.
14- Clinical Features of Malignant Melanoma in an Iranian Population. 9th World Congress
on Cancers of the Skin, Seville, Spain, May 7-10, 2003.
15- Obstacles to Obtaining High Quality Research Papers for Publication: The Iranian Experience. Regional Conference on Medical Journals in the WHO Eastern
Mediterranean Region (EMRO), Cairo, Egypt, October 7-9,2003.
16- The Beneficial and Detrimental Effects of Linoleic Acid on Autoimmune Disorders. The 2nd Scientific Conference for Medical Students in the GCC Countries, Al-Ain, UAE,
17- Mortality in a Dermatology Ward: A Ten- Year Study (1990-2000) in Shiraz, Iran. 2nd
Qatar International Trauma Care, Disaster and Emergency Medicine Conference,
18- A Review of Clinical and Vaccine Trials on Cutaneous Leishmaniasis in Iran. 9th
International Congress of Dermatology, Beijing, China, May 19-22, 2004.
19- Medical Journalism and the Informed Consent Process: Where Do We Stand? 2nd
Regional Conference on Medical Journal in the EMR, Riyadh, Saudia Aranbia,
20- Clinical Features of 150 Patients with Pemphigus in Southern Iran. 13th Congress of the
European Academy of Dermatology and Venereology, Florence, Italy, November,
21-Serum Zinc Levels in Cutaneous Leishmaniasis. Third World Congress on
Leishmaniosis, Sicily, Italy, April 10-15, 2005.
22-The Prevalence of Personality Disorders in Psoriasis. The 14th Congress of the
European Academy of Dermatology & Venereology, London, U.K, October 12-16, 2005.
23-Assessment of Quality of Life in Patients with Melasma. 10th Congress of the Pan Arab
League of Dermatologists, Taiz, Yemen, August 31 - September 3, 2006.
24-The Eastern Mediterranean Association of Medical Editors (EMAME): A new partner in the world of medical journalism. 2nd Mediterranean Editors and Translators' Meeting,
Barcelona, Spain, October 27-28, 2006. 25-Editorship in our Region: Challenges and Possible Solutions. National Conference on
Medical Editing, Rawalpindi, Pakistan, April 23-25, 2007.
26-History of Dermatology in Iran. The 16th Congress of the European Academy of
Dermatology and Venereology, Vienna, Austria, May 16-20, 2007.
27-Ethics in Clinical Trials. European Medical Writers Association Annual Conference,
Vienna, Austria, May 22-26, 2007. 28-Cutaneous Leishmaniasis. 21st World Congress of Dermatology, Buenos Aires,
PUBLICATIONS:
1- Sodaify M, Baghestani S, Handjani F, Sotoodeh M. Erythromelanosis follicularis faciei
et colli. Int J Dermatol 1994; 33: 643-644. 2- Handjani F. Granuloma annulare. The Practitoner East Mediterr Edit 1994; 5: 714.
3- Emad M, Handjani F, Baghestani S, Sotoodeh M. Lichen planus of the eyelid. Eur J
4- Namian AM, Handjani F. Lupus vulgaris of the breast. J Yasuj Univ Med Sci 1996; 1:
5- Sodaifi M, Handjani F, Shahriari M et al. Multiple scalp nodules: initial manifestation of
acute lymphoblastic leukemia. J Yasuj Univ Med Sci 1996; 3: 47-51 (in Farsi). 6-Salmanpour R, Handjani F, Delir S, Motamedi- Gettner S. Tinea manum due to
Trichophyton mentagrophytes. The Practitioner East Mediterr Edit 1997; 8: 161-163. 7- Handjani F, Cutis verticis gyrata. The Practitoner East Mediterr Edit 1997; 8: 323.
8-Handjani F, Sodaifi M, Seif A, Shariat S. Becker’s nevus and breast hypoplasia: report of
a case and review of the literature. J Yasuj Univ Med Sci 1997; 5: 55-60 (in Farsi). 9-Baghestani S, Handjani F, Sodeifi M, Kumar PV. Post–Kala–azar dermal leishmaniasis.
10-Delir S, Handjani F, Emad M, Ardehali S. Vulvar myiasis due to Wohlfahrtia
magnifica. Clin Exp Dermatol 1999; 24: 279-280. 11-Zerehsaz F, Salamanpour R, Handjani F. et al. A double – blind randomized clinical
trial of a topical herbal extract (Z-HE) vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in Iran. Int J Dermatol 1999; 38: 610-612. 12-Salmanpour R, Handjani F, Zerehsaz F. et al. Erysipeloid leishmaniasis: an unusual
clinical presentation. Eur J Dermatol 1999; 9: 458-459. 13-Handjani F, Delir S, Sodaifi M, Kumar PV. Post-BCG vaccination lupus vulgaris. Br J
14- Salmanpour R, Handjani F, Nouhpisheh MK: Comparative study of the efficacy of oral
ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis. J Dermatol Treat 2001; 12:159-162. 15- Kasraee B, Handjani F, Aslani FS. Enhancement of the depigmenting effect of
hydroquinone and 4- hydroxyanisole by all-trans-retinoic acid (tretinoin): The impairment of the glutathione-dependent cytoprotection? Dermatology 2003; 206(4):289-91. 16- Namazi MR, Handjani F. Angioma serpiginosum. Dermatol Online J 2003; 9(3):19.
17- Motazedian M.H, Karamian M, Ardehali S, Handjani F. Characterization of leishmania
parasites from archived Giemsa-stained slides using nested polymerase chain reaction. Journal of Medical Research 2004; 2:1-9 (in Farsi). 18- Imanieh MH, Moravej H, Kashef S, Handjani F, et al. Cow's milk allergy in infantile
colic. Armaghane-Danesh 2004;9:46-56 (in Farsi). 19- Aghaei S, Salmanpour R, Handjani F, Monabati A, Mazharinia N, Dastgheib L.
Ulcerated disseminated cutaneous leishmaniasis associated with vitiligo, hypothyroidism, and diabetes mellitus in a patients with Down syndrome. Dermatol Online J 2004;10(2):21. 20-Dehghani F, Merat A, Panjehshahin MR, Handjani F. Healing effect of garlic extract on
warts and corns. Int J Dermatol. 2005;44(7):612-5. 21-Namazi MR, Handjani F, Sodaifi M, The potential utility of statins as novel weapons
against graft-versus-host disease. Med Hypotheses. 2005;65(6):1203-4. 22- Kasraee B, Handjani F, Parhizgar A, Omrani GR, Fallahi MR, Amini M, Nikbakhsh M, Tran
C, Hugin A, Sorg O, Saurat JH. Topical methimazole as a new treatment for postinflammatory hyperpigmentation: report of the first case. Dermatology. 2005;211(4):360-2. 23-Motamedifar M, Handjani F, Hadi N, et al. Seroprevalence of varicella-zoster virus in children
from Shiraz-Iran. Iran J Immunol 2006;3:43-46. 24- Kashef MA, Kashef S, Handjani F, Karimi M. Hodgkin lymphoma developing in a 4.5-
year-old girl with hyper-IgE syndrome. Pediatr Hematol Oncol. 2006;23(1):59-63. 25- Namazi MR, Handjani F, Amirahmadi M. Increased oxidative activity from hydrogen
peroxide may be the cause of the predisposition to cataracts among patients with atopic dermatitis. Med Hypotheses. 2006;66(4):863-4. 26- Namazi MR, Handjani F. Lithium: a potential treatment for hyper-IgE syndrome.
27- Kasraee B, Fallahi MR, Ardekani GS, Ebrahimi S, Doroudchi G, Omrani GR, Handjani F,
Amini M, Tanideh N, Haddadi M, Nikbakhsh M, Jahanbani S, Tran C, Sorg O, Saurat JH. Retinoic acid synergistically enhances the melanocytotoxic and depigmenting effects of monobenzylether of hydroquinone in black guinea pig skin. Exp Dermatol. 28-Safaee Ardekani G, Ebrahimi S, Amini M, Sari Aslani F, Handjani F, et al. Topical Captopril as a Novel Agent Against Hypertrophic Scar Formation in New Zealand White Rabbit Skin. Wounds. 2008:20(4):101-106.

Source: http://research.sums.ac.ir/icarusplus/export/sites/research/int-office/cvhandjani.pdf

New proposed spc

BIJSLUITER: INFORMATIE VOOR DE GEBRUIK(ST)ER Lodotra 1 mg, tabletten met gereguleerde afgifte Lodotra 2 mg, tabletten met gereguleerde afgifte Lodotra 5 mg, tabletten met gereguleerde afgifte prednison - Lees de hele bijsluiter zorgvuldig door voordat u start met het innemen van dit - Bewaar deze bijsluiter. Het kan nodig zijn om deze nog eens door te lezen. - Heeft u nog vragen,

optumrxpharmacyinfocus.com

Drug pipline Your costs can change dramatically when new medications come to market. So we keep careful watch on new drug launches, as well as on medications expected to gain approval in the next several months. The Pipeline Report contains a sampling of the initial assessments of recent and upcoming medication launches from news outlets andexpert analysts around the industry. We try to cap

Copyright © 2010-2014 Predicting Disease Pdf